Biocompatible and blood-brain barrier permeable carbon dots for inhibition of Aβ fibrillation and toxicity, and BACE1 activity

Xu Han, Zhifeng Jing, Wei Wu, Bing Zou, Zhili Peng, Pengyu Ren, Athula Wikramanayake, Zhongmin Lu, Roger Leblanc

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Amyloid-β peptide (Aβ) fibrillation is pathologically associated with Alzheimer's disease (AD), and this has resulted in the development of an Aβ inhibitor which is essential for the treatment of AD. However, the design of potent agents which can target upstream secretases, inhibit Aβ toxicity and aggregation, as well as cross the blood-brain barrier remains challenging. In, this research carbon dots for AD treatment were investigated in vitro using experimental and computational methods for the first time. The results presented here demonstrate a novel strategy for the discovery of novel antiamyloidogenic agents for AD treatments.

Original languageEnglish (US)
Pages (from-to)12862-12866
Number of pages5
JournalNanoscale
Volume9
Issue number35
DOIs
StatePublished - Sep 21 2017

Fingerprint

Toxicity
Carbon
Amyloid Precursor Protein Secretases
Computational methods
Amyloid
Peptides
Agglomeration
Blood-Brain Barrier

ASJC Scopus subject areas

  • Materials Science(all)

Cite this

Biocompatible and blood-brain barrier permeable carbon dots for inhibition of Aβ fibrillation and toxicity, and BACE1 activity. / Han, Xu; Jing, Zhifeng; Wu, Wei; Zou, Bing; Peng, Zhili; Ren, Pengyu; Wikramanayake, Athula; Lu, Zhongmin; Leblanc, Roger.

In: Nanoscale, Vol. 9, No. 35, 21.09.2017, p. 12862-12866.

Research output: Contribution to journalArticle

Han, Xu ; Jing, Zhifeng ; Wu, Wei ; Zou, Bing ; Peng, Zhili ; Ren, Pengyu ; Wikramanayake, Athula ; Lu, Zhongmin ; Leblanc, Roger. / Biocompatible and blood-brain barrier permeable carbon dots for inhibition of Aβ fibrillation and toxicity, and BACE1 activity. In: Nanoscale. 2017 ; Vol. 9, No. 35. pp. 12862-12866.
@article{d6bb8c136394473bb2043dac667a9057,
title = "Biocompatible and blood-brain barrier permeable carbon dots for inhibition of Aβ fibrillation and toxicity, and BACE1 activity",
abstract = "Amyloid-β peptide (Aβ) fibrillation is pathologically associated with Alzheimer's disease (AD), and this has resulted in the development of an Aβ inhibitor which is essential for the treatment of AD. However, the design of potent agents which can target upstream secretases, inhibit Aβ toxicity and aggregation, as well as cross the blood-brain barrier remains challenging. In, this research carbon dots for AD treatment were investigated in vitro using experimental and computational methods for the first time. The results presented here demonstrate a novel strategy for the discovery of novel antiamyloidogenic agents for AD treatments.",
author = "Xu Han and Zhifeng Jing and Wei Wu and Bing Zou and Zhili Peng and Pengyu Ren and Athula Wikramanayake and Zhongmin Lu and Roger Leblanc",
year = "2017",
month = "9",
day = "21",
doi = "10.1039/c7nr04352j",
language = "English (US)",
volume = "9",
pages = "12862--12866",
journal = "Nanoscale",
issn = "2040-3364",
publisher = "Royal Society of Chemistry",
number = "35",

}

TY - JOUR

T1 - Biocompatible and blood-brain barrier permeable carbon dots for inhibition of Aβ fibrillation and toxicity, and BACE1 activity

AU - Han, Xu

AU - Jing, Zhifeng

AU - Wu, Wei

AU - Zou, Bing

AU - Peng, Zhili

AU - Ren, Pengyu

AU - Wikramanayake, Athula

AU - Lu, Zhongmin

AU - Leblanc, Roger

PY - 2017/9/21

Y1 - 2017/9/21

N2 - Amyloid-β peptide (Aβ) fibrillation is pathologically associated with Alzheimer's disease (AD), and this has resulted in the development of an Aβ inhibitor which is essential for the treatment of AD. However, the design of potent agents which can target upstream secretases, inhibit Aβ toxicity and aggregation, as well as cross the blood-brain barrier remains challenging. In, this research carbon dots for AD treatment were investigated in vitro using experimental and computational methods for the first time. The results presented here demonstrate a novel strategy for the discovery of novel antiamyloidogenic agents for AD treatments.

AB - Amyloid-β peptide (Aβ) fibrillation is pathologically associated with Alzheimer's disease (AD), and this has resulted in the development of an Aβ inhibitor which is essential for the treatment of AD. However, the design of potent agents which can target upstream secretases, inhibit Aβ toxicity and aggregation, as well as cross the blood-brain barrier remains challenging. In, this research carbon dots for AD treatment were investigated in vitro using experimental and computational methods for the first time. The results presented here demonstrate a novel strategy for the discovery of novel antiamyloidogenic agents for AD treatments.

UR - http://www.scopus.com/inward/record.url?scp=85029517288&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029517288&partnerID=8YFLogxK

U2 - 10.1039/c7nr04352j

DO - 10.1039/c7nr04352j

M3 - Article

C2 - 28850143

AN - SCOPUS:85029517288

VL - 9

SP - 12862

EP - 12866

JO - Nanoscale

JF - Nanoscale

SN - 2040-3364

IS - 35

ER -